TELIX Pharmaceuticals Ltd (TLX) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.066x

Based on the latest financial reports, TELIX Pharmaceuticals Ltd (TLX) has a cash flow conversion efficiency ratio of 0.066x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$27.98 Million ≈ $19.80 Million USD) by net assets (AU$421.94 Million ≈ $298.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

TELIX Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how TELIX Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TLX total liabilities for a breakdown of total debt and financial obligations.

TELIX Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of TELIX Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Nickel Industries Ltd AU:NIC	0.036x
Brookdale Senior Living Inc NYSE:BKD	-0.796x
Adecco Group AG F:ADIA	0.140x
Acerinox MC:ACX	0.145x
National Storage Affiliates Trust NYSE:NSA	0.063x
Dorman Products Inc NASDAQ:DORM	0.028x
Clicks JSE:CLS	0.621x
China Baoan Group Co Ltd SHE:000009	0.010x

Annual Cash Flow Conversion Efficiency for TELIX Pharmaceuticals Ltd (2017–2024)

The table below shows the annual cash flow conversion efficiency of TELIX Pharmaceuticals Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see TLX stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	AU$568.21 Million ≈ $402.05 Million	AU$43.03 Million ≈ $30.45 Million	0.076x	-52.79%
2023-12-31	AU$148.91 Million ≈ $105.36 Million	AU$23.88 Million ≈ $16.90 Million	0.160x	+119.29%
2022-12-31	AU$76.92 Million ≈ $54.42 Million	AU$-63.97 Million ≈ $-45.26 Million	-0.832x	+94.89%
2021-12-31	AU$3.64 Million ≈ $2.58 Million	AU$-59.33 Million ≈ $-41.98 Million	-16.290x	-65771.77%
2020-12-31	AU$79.02 Million ≈ $55.91 Million	AU$1.96 Million ≈ $1.39 Million	0.025x	+107.52%
2019-12-31	AU$70.73 Million ≈ $50.05 Million	AU$-23.33 Million ≈ $-16.51 Million	-0.330x	+15.88%
2018-12-31	AU$52.90 Million ≈ $37.43 Million	AU$-20.75 Million ≈ $-14.68 Million	-0.392x	-220.50%
2017-12-31	AU$49.29 Million ≈ $34.88 Million	AU$-6.03 Million ≈ $-4.27 Million	-0.122x	--

About TELIX Pharmaceuticals Ltd

AU:TLX Australia Biotechnology

Market Cap

$3.69 Billion

AU$5.21 Billion AUD

Market Cap Rank

#4679 Global

#115 in Australia

Share Price

AU$15.57

Change (1 day)

+3.80%

52-Week Range

AU$8.63 - AU$29.16

All Time High

AU$31.14